专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08618043B2 Use of ADNF polypeptides for treating anxiety and depression 有权
标题翻译：使用ADNF多肽治疗焦虑和抑郁
公开(公告)号：US08618043B2
公开(公告)日：2013-12-31
申请号：US13080412
申请日：2011-04-05
申请人： Illana Gozes , Roy N. Alcalay , Inna Divinski , Eliezer Giladi
发明人： Illana Gozes , Roy N. Alcalay , Inna Divinski , Eliezer Giladi
IPC分类号： A61K38/00 , A61K51/00
CPC分类号： A61K38/18
摘要： This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions.
摘要翻译：本发明涉及ADNF多肽在治疗焦虑和/或抑郁症中的应用。本发明还涉及使用ADNF多肽作用和靶相互作用机制的药物发现测定，以及药物的制备，应用方法和制剂。本发明的实施方案通过以足以改善出生后表现的量施用NAP（衍生自活性依赖性神经营养因子（ADNF III）的8-氨基酸肽）来提供预防和/或治疗受试者的焦虑和抑郁症的方法。 ADNF多肽包括ADNF I和ADNF III（也称为ADNP）多肽，类似物，亚序列和D-氨基酸形式（完全D-氨基酸肽或混合D-和L-氨基酸肽）和组合其含有它们各自的活性核心位点并提供神经保护和抗焦虑功能。

2. 发明申请

US20120015878A1 USE OF ADNF POLYPEPTIDES FOR TREATING ANXIETY AND DEPRESSION 有权
标题翻译： ADNF多肽用于治疗恶心和呕吐的用途
公开(公告)号：US20120015878A1
公开(公告)日：2012-01-19
申请号：US13080412
申请日：2011-04-05
申请人： Illana Gozes , Roy N. Alcalay , Inna Divinski , Eliezer Giladi
发明人： Illana Gozes , Roy N. Alcalay , Inna Divinski , Eliezer Giladi
IPC分类号： A61K38/18 , A61K38/10 , A61K31/7088 , G01N33/567 , A61P25/22 , A61P25/24 , A61K49/00 , C40B30/04 , A61K38/08 , C07K7/06
CPC分类号： A61K38/18
摘要： This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions.
摘要翻译：本发明涉及ADNF多肽在治疗焦虑和/或抑郁症中的应用。本发明还涉及使用ADNF多肽作用和靶相互作用机制的药物发现测定，以及药物的制备，应用方法和制剂。本发明的实施方案通过以足以改善出生后表现的量施用NAP（衍生自活性依赖性神经营养因子（ADNF III）的8-氨基酸肽）来提供预防和/或治疗受试者的焦虑和抑郁症的方法。 ADNF多肽包括ADNF I和ADNF III（也称为ADNP）多肽，类似物，亚序列和D-氨基酸形式（完全D-氨基酸肽或混合D-和L-氨基酸肽）和组合其含有它们各自的活性核心位点并提供神经保护和抗焦虑功能。

3. 发明授权

US07960334B2 Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia 有权
标题翻译： ADNF III多肽用于治疗精神疾病和障碍，包括精神分裂症的应用
公开(公告)号：US07960334B2
公开(公告)日：2011-06-14
申请号：US10547986
申请日：2004-03-11
申请人： Illana Gozes , Roy N. Alcalay , Inna Divinski , Eliezer Giladi
发明人： Illana Gozes , Roy N. Alcalay , Inna Divinski , Eliezer Giladi
IPC分类号： A61K38/00 , A61K51/00
CPC分类号： A61K38/18
摘要： This invention relates to the use of ADNF III polypeptides in the treatment of mental diseases or disorders, including schizophrenia. Embodiments of the invention provide methods for treating mental disorders, including schizophrenia, in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to reduce or eliminate symptoms. The ADNF III polypeptides include polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain the active core sites and provide neuroprotective and anti-schizophrenic functions.
摘要翻译：本发明涉及ADNF III多肽在治疗精神疾病或病症（包括精神分裂症）中的应用。本发明的实施方案提供了通过以足以减少或消除症状的量施用NAP，衍生自活性依赖性神经营养因子（ADNF III）的8-氨基酸肽来治疗受试者的精神障碍（包括精神分裂症）的方法。 ADNF III多肽包括多肽，类似物，亚序列和D-氨基酸形式（完全D-氨基酸肽或混合的D-和L-氨基酸肽）及其组合，其含有活性核心位点并提供神经保护和抗精神分裂症功能。

4. 发明申请

US20070054847A1 Use of adnf polypeptides for treating anxiety and depression 有权
标题翻译：使用adnf多肽治疗焦虑和抑郁
公开(公告)号：US20070054847A1
公开(公告)日：2007-03-08
申请号：US10547986
申请日：2004-03-11
申请人： Illana Gozes , Roy Alcalay , Inna Divinski , Eliezer Giladi
发明人： Illana Gozes , Roy Alcalay , Inna Divinski , Eliezer Giladi
IPC分类号： A61K38/17 , A61K38/10
CPC分类号： A61K38/18
摘要： This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions.
摘要翻译：本发明涉及ADNF多肽在治疗焦虑和/或抑郁症中的应用。本发明还涉及使用ADNF多肽作用和靶相互作用机制的药物发现测定，以及药物的制备，应用方法和制剂。本发明的实施方案通过以足以改善出生后表现的量施用NAP（衍生自活性依赖性神经营养因子（ADNF III）的8-氨基酸肽）来提供预防和/或治疗受试者的焦虑和抑郁症的方法。 ADNF多肽包括ADNF I和ADNF III（也称为ADNP）多肽，类似物，亚序列和D-氨基酸形式（完全D-氨基酸肽或混合D-和L-氨基酸肽）和组合其含有它们各自的活性核心位点并提供神经保护和抗焦虑功能。

5. 发明授权

US08377875B2 Therapeutics based on tau/microtubule dynamics 有权
标题翻译：基于tau /微管动力学的治疗
公开(公告)号：US08377875B2
公开(公告)日：2013-02-19
申请号：US12523035
申请日：2008-01-10
申请人： Illana Gozes , Maya Maor , Saar Oz , David Dangoor , Inna Divinski
发明人： Illana Gozes , Maya Maor , Saar Oz , David Dangoor , Inna Divinski
IPC分类号： A61K38/22 , A61P3/04 , A61P25/28
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08
摘要： The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics.
摘要翻译：本发明基于新型神经保护肽的发现。此外，本发明还取决于NAP肽增强tau与脑特异性β微管蛋白亚基的关联的发现。此外，NAP部分通过影响微管蛋白的酪氨酸修饰微管组装和动力学。本发明提供了用于治疗和预防神经元病症的组合物和方法，包括NAP结合和tau结合剂，tau肽模拟物，NAP样和NAP样tau肽模拟物。

6. 发明申请

US20100303785A1 NOVEL THERAPEUTICS BASED ON TAU/MICROTUBULE DYNAMICS 有权
标题翻译：基于TAU / MICROTUBULE DYNAMICS的新型治疗方法
公开(公告)号：US20100303785A1
公开(公告)日：2010-12-02
申请号：US12523035
申请日：2008-01-10
申请人： Illana Gozes , Maya Maor , Saar Oz , David Dangoor , Inna Divinski
发明人： Illana Gozes , Maya Maor , Saar Oz , David Dangoor , Inna Divinski
IPC分类号： A61K38/54 , C07K7/06 , C07K7/08 , C07K14/00 , A61K38/08 , A61K38/16 , A61P25/24 , A61P25/18 , A61K38/10 , A61K38/48 , A61K38/53 , A61K31/16 , A61K38/43 , C12Q1/00
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08
摘要： The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics.
摘要翻译：本发明基于新型神经保护肽的发现。此外，本发明还取决于NAP肽增强tau与脑特异性β微管蛋白亚基的关联的发现。此外，NAP部分通过影响微管蛋白的酪氨酸修饰微管组装和动力学。本发明提供了用于治疗和预防神经元病症的组合物和方法，包括NAP结合和tau结合剂，tau肽模拟物，NAP样和NAP样tau肽模拟物。

7. 发明授权

US08017578B2 Orally active peptides that prevent cell damage and death 有权
标题翻译：口服活性肽，可防止细胞损伤和死亡
公开(公告)号：US08017578B2
公开(公告)日：2011-09-13
申请号：US12102760
申请日：2008-04-14
申请人： Douglas Brenneman , Illana Gozes , Catherine Y. Spong , Albert Pinhasov , Eliezer Giladi
发明人： Douglas Brenneman , Illana Gozes , Catherine Y. Spong , Albert Pinhasov , Eliezer Giladi
IPC分类号： A61K38/08 , C07K7/06
CPC分类号： A61K38/04 , A61K38/185
摘要： This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
摘要翻译：本发明提供了包含活性核心位点的ADNF多肽，所述活性核心位点包含至少一个D-氨基酸。本发明还提供了包含包含活性核心位点的ADNF多肽的药物组合物，所述活性核心位点包含至少一个D-氨基酸。特别地，本发明的药物组合物是口服活性的。本发明还提供了使用ADNF多肽和本发明的药物组合物减少神经元细胞死亡的方法，用于降低氧化应激的方法以及用于降低与胎儿酒精综合征相关的病症的方法。

8. 发明授权

US07384908B1 Orally active peptides that prevent cell damage and death 有权
标题翻译：口服活性肽，可防止细胞损伤和死亡
公开(公告)号：US07384908B1
公开(公告)日：2008-06-10
申请号：US10049587
申请日：2000-08-17
申请人： Douglas E. Brenneman , Catherine Y. Spong , Illana Gozes , Albert Pinhasov , Eliezer Giladi
发明人： Douglas E. Brenneman , Catherine Y. Spong , Illana Gozes , Albert Pinhasov , Eliezer Giladi
IPC分类号： A01N37/18 , A61K38/00
CPC分类号： A61K38/04 , A61K38/185
摘要： This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
摘要翻译：本发明提供了包含活性核心位点的ADNF多肽，所述活性核心位点包含至少一个D-氨基酸。本发明还提供了包含包含活性核心位点的ADNF多肽的药物组合物，所述活性核心位点包含至少一个D-氨基酸。特别地，本发明的药物组合物是口服活性的。本发明还提供了使用ADNF多肽和本发明的药物组合物减少神经元细胞死亡的方法，用于降低氧化应激的方法以及用于降低与胎儿酒精综合征相关的病症的方法。

9. 发明申请

US20080194488A1 ORALLY ACTIVE PEPTIDES THAT PREVENT CELL DAMAGE AND DEATH 有权
标题翻译：预防细胞损伤和死亡的活性物质
公开(公告)号：US20080194488A1
公开(公告)日：2008-08-14
申请号：US12102760
申请日：2008-04-14
申请人： Illana Gozes , Albert Pinhasov , Eliezer Giladi , Douglas E. Brenneman , Catherine Y. Spong
发明人： Illana Gozes , Albert Pinhasov , Eliezer Giladi , Douglas E. Brenneman , Catherine Y. Spong
IPC分类号： A61K38/08
CPC分类号： A61K38/04 , A61K38/185
摘要： This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
摘要翻译：本发明提供了包含活性核心位点的ADNF多肽，所述活性核心位点包含至少一个D-氨基酸。本发明还提供了包含包含活性核心位点的ADNF多肽的药物组合物，所述活性核心位点包含至少一个D-氨基酸。特别地，本发明的药物组合物是口服活性的。本发明还提供了使用ADNF多肽和本发明的药物组合物减少神经元细胞死亡的方法，用于降低氧化应激的方法以及用于降低与胎儿酒精综合征相关的病症的方法。

10. 发明授权

US08067369B2 Protection of the retina against laser injury by NAP and related peptides 有权
标题翻译：保护视网膜免受NAP和相关肽的激光损伤
公开(公告)号：US08067369B2
公开(公告)日：2011-11-29
申请号：US12280471
申请日：2006-04-20
申请人： Illana Gozes , Michael Belkin
发明人： Illana Gozes , Michael Belkin
IPC分类号： A61K38/18 , A61K38/08
CPC分类号： A61K38/18 , G01N2800/40
摘要： This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions.
摘要翻译：本发明涉及ADNF多肽在治疗激光诱导的视网膜损伤和相关病症中的应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式